Navigation Links
Cannabis Science (CBIS) Moves Forward with Critical Support of Landmark Federal Cannabis Legislative Initiative
Date:12/2/2013

COLORADO SPRINGS, Colo., Dec. 2, 2013 /PRNewswire/ -- (NASDAQ OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development, is a key leader in the private sector challenge to end the restrictions on cannabis drug development and research in the U.S.  "The Cannabinoid Scientific Research and Development Act," which will be submitted for congressional review in the U.S. Senate and House of Representatives by the end of January 2014, is landmark legislation seeking equal treatment for cannabinoid scientific research.  In addition, the legislation aims to provide the framework for the clinical investigation of the hundreds of strains of cannabis and their constituent cannabinoids regarding their medical efficacy on a wide range of life-threatening, chronic, and infectious diseases. 

The legislation also seeks to provide "an informed clinical environment for physicians, researchers and consumers to make effective clinical choices regarding their therapeutic treatments for a variety of diseases," said Dr. Robert Melamede, President, Cannabis Science.  "We need rational federal standards based upon science to replace inadequate public policies rooted in the misperceptions of the past," Dr. Melamede added.

The legislation directs the U.S. Secretary of Health and Human Services to develop guidelines, standards, and regulations that provide the framework for development of cannabis research.  It also asks that this new regulatory framework begin rapidly after the removal of legal and regulatory obstacles for that research and that these guidelines follow a milestone 2007 Drug Enforcement Administrative Law ruling overturning the prejudicial procedures that effectively disallow domestic cannabis research and drug development.

Cannabis Science views these federal legislative developments as a critical part of the growth and development of its domestic biotechnology business.  "We need the same consideration in terms of the ability to conduct clinical trials and to develop therapies as other firms in the biotechnology sector," said Dr. Dorothy Bray, CEO of Cannabis Science.  Dr. Bray continued, "We also need to level the playing field to match rapidly changing regulatory environment in other countries that either have or are accommodating cannabis research."

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and HIV related cancers such as Kaposi's sarcoma.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com

Investment Inquiries
Robert Kane, CFO & Director
rkane@cannabisscience.com
561.420.4824


'/>"/>
SOURCE Cannabis Science, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GrowLife Debuts First Kiosk-Based Payment, Cash Management, and Regulatory Compliance Technology for Legal Cannabis Dispensaries
2. Cannabis Science Announces The Depository Trust Company (DTC) Lifts Share Trading "Chill" Effective Immediately
3. X-Change Corp. Delighted with DOJs Historic Shift Toward Non-Interference Within State Cannabis Regulatory Environments; Sees Green Light for Companys Patient-Driven Medical Cannabis Operations Under State Laws
4. X-Change Corporation Signs Multi-Million Dollar Agreement for Multi-State Product Release Licensing, Medical Cannabis Dispensary Management, and Cultivation Consulting
5. American Drug War II: Cannabis Destiny is IMDBs Highest Rated 2013 Documentary
6. Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Companys Drug Development Pipeline
7. Virogens New Business Unit, "The Cannabis Connection," to Focus on High-End Medicinal Marijuana Dispensary Niche within $15-20 Billion Legal Marijuana Market
8. Virogen Announces Launch of New Business Unit, "The Cannabis Connection", and Sets Sights on $15-20 Billion Legal Marijuana Market
9. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
10. Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
11. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a ... does not. Yisrayl says with so many titles and names for the Creator, it’s ... with a little Scripture, backed with a lot of research, the truth is undeniable. ...
(Date:4/28/2017)... York, New York (PRWEB) , ... April 28, ... ... high-quality anti-aging skincare and advanced nutraceutical supplements, through its Nova Skin ... cream provides the hydrating benefits of a moisturizer with the power of an ...
(Date:4/28/2017)... MEMPHIS, Tenn. (PRWEB) , ... April 28, 2017 , ... ... VeinViewer® system, today announced an alliance with B. Braun Medical Inc. , a ... central role in patient care with as many as 90 percent of hospital patients ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, ... the heels of Thinksport’s award-winning sunscreen they’ve used the same scientific approach to ... , Countless deodorants flood the aisles that contain harmful chemicals that should be ...
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs announced ... Lincoln, Neb. area this year. , The first new location will open at ... will open at 84th and Northern Lights Drive this fall. And the third location ...
Breaking Medicine News(10 mins):